Background
A body surface area (BSA) of 1.7 m2 was considered as the lower limit to implant a CardioWest Total Artificial Heart
(TAH). We reviewed our experience with the TAH in patients with a BSA of less than
1.7 m2.
Methods
From April 1986 to May 2003, among 149 patients implanted with a TAH in our institution,
30 had a BSA of less than 1.7 m2 (Group I). Results were compared with the remaining 119 patients (Group II).
Results
One patient in Group I experienced a fitting problem and was left with the chest open.
Otherwise, in this group, the Day 1 cardiac index averaged 3.6 ± 0.6 liter/min/m2, which was significantly higher than the 2.8 ± 0.36 liter/min/m2 observed in Group II. Post-implantation central venous pressure and mean arterial
pressure were similar in both groups: 14.7 ± 3.8 mm Hg vs 14.5 ± 4 mm Hg and 87 ±
23 mm Hg vs 88 ± 19 mm Hg, respectively. In Group I, survival on the device dramatically
increased from 9% before 1992, to 36% between 1992 and 1997 and finally reached 75%
after then. In the meantime, for the same time periods, global survival to hospital
discharge increased from 9% to 36% and reached 50% after 1997. In Group II, global
survival to hospital discharge was 25.5% before 1992, 34.6% between 1993 and 1997,
and reached 52% thereafter.
Conclusion
The CardioWest TAH can be used in patients with a BSA between 1.5 m2 and 1.7 m2 with few fitting problems. In this group of patients, results are similar to those
obtained in patients with a BSA greater than 1.8 m2.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The Journal of Heart and Lung TransplantationAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The CardioWest total artificial heart as a bridge to transplantation.Semin Thorac Cardiovasc Surg. 2000; 12: 238-242
- Comparison of the CardioWest total artificial heart, the Novacor left ventricular assist system and the Thoratec ventricular assist system in bridge to transplantation.Ann Thorac Surg. 2001; 71 (discussion S114–5): S92-S97
- Factors affecting survival in total artificial heart recipients before transplantation.Circulation. 1990; 82: IV322-IV327
- Implantation technique for the CardioWest total artificial heart.Ann Thorac Surg. 1999; 68: 698-704
- Control and treatment of hemostasis in cardiovascular surgery. The experience of La Pitie Hospital with patients on total artificial heart.Int J Artif Organs. 1995; 18: 633-648
- Hemodynamic characteristics of the Jarvik-7 total artificial heart.Circulation. 1989; 80: III152-III157
- Circulatory support for fulminant myocarditis.Eur J Cardiothorac Surg. 2003; 24: 399-403
- Mechanical circulatory support for adolescent patients.Can J Cardiol. 2003; 19: 409-412
- Cardiac replacement with a total artificial heart as a bridge to transplantation.N Engl J Med. 2004; 351: 859-867
- Development of a custom designed TAH using rapid prototyping.ASAIO J. 1997; 43: M647-M650
- Initial experience with the AbioCor implantable replacement heart system.J Thorac Cardiovasc Surg. 2004; 127: 131-141
- Bridge to transplantation with the Jarvik-7 (CardioWest) total artificial heart.J Heart Lung Transplant. 2003; 22: 1296-1303
- Synthetic membrane neo-pericardium facilitates total artificial heart explantation.J Heart Lung Transplant. 2001; 20: 654-656
- Expanded polytetrafluoroethylene membranes to wrap surfaces of circulatory support devices in patients undergoing bridge to heart transplantation.Eur J Cardiothorac Surg. 2001; 19: 302-306
Article info
Publication history
Published online: May 09, 2005
Accepted:
January 12,
2005
Received in revised form:
December 23,
2004
Received:
June 28,
2004
Identification
Copyright
© 2005 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.